Loading...
Loading...
CELUW| Name | Value |
|---|---|
| Revenues | 4.1M |
| Cost of Revenue | 5.2M |
| Gross Profit | -1.1M |
| Operating Expense | 30.6M |
| Operating I/L | 17.5M |
| Other Income/Expense | 7.0M |
| Interest Income | 0.2M |
| Pretax | 24.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 24.4M |
Celularity Inc. is a clinical-stage biotechnology company specializing in the development of off-the-shelf placental-derived allogeneic cell therapies for cancer, immune, and infectious diseases. The company's revenue streams come from the sale and licensing of products used in surgical and wound care markets, such as Biovance and Interfyl, as well as the collection of stem cells from umbilical cords and placentas for storage under the LifebankUSA brand. Additionally, Celularity is involved in the development and commercialization of various therapeutic programs, including placental-derived CAR-T therapy, natural killer (NK) cell treatments, and mesenchymal-like adherent stromal cell therapies.
